Parse

Parse indexes AI recommendations so brands know where they stand.

Products

  • Brands
  • Markets
  • Integrations
  • Work with us
  • Pricing
  • MCP

Resources

  • Research
  • Methodology
  • Blog

© 2026 Parse. All rights reserved.

LegalPrivacy PolicyTerms of Service
Parse
Work with usPricing
Sign inCheck your brand
  1. Brands
  2. Alnylam Pharmaceuticals
BrandsAlnylam Pharmaceuticals

How AI describes Alnylam Pharmaceuticals

Data as of Aug 25, 2026 · Based on 3,181,687 AI responses across 10,525 prompts · See how Parse measures this

Alnylam Pharmaceuticals logoAlnylam Pharmaceuticalsalnylam.com

Alnylam is a biopharmaceutical company that develops RNA interference (RNAi) therapeutics, an innovative class of medicines that silence specific genes to treat diseases at their source. The company focuses on both rare and prevalent diseases, with a robust pipeline of investigational RNAi therapies in several therapeutic areas.

Parse Score

47.8
Strength7/ 100
Reach31/ 100
Authority32/ 100

Work at Alnylam Pharmaceuticals?

Claim this profile for the full report: every prompt where Alnylam Pharmaceuticals appears, who is gaining, and what AI says about you. Claiming is free. Ongoing monitoring is a paid upgrade.

Verified with a work email.

Sources

finance.yahoo.com shapes more of what AI says about Alnylam Pharmaceuticals than any other source, at 50% of its citations.

nct-cbnw.com · pmc.ncbi.nlm.nih.gov

Always know where you stand in AI

Monitor Alnylam Pharmaceuticals